Two RNA vaccines will be useful as US infections surge, but the speedy authorizations complicate clinical trials. A week after granting an emergency-use authorization for the country’s first COVID-19 vaccine, US regulators have followed with a second: another RNA vaccine, this one made by Moderna of Cambridge, Massachusetts. The emergency-use authorization followed quickly after a…
Read More